Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas

Future Oncology

Volumn 4, Issue 4, 2008, Pages 525-534

  Shai, Ruty Mehrian ^a   Reichardt, Juergen K V ^b   Chen, Thomas C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Brain; Cancer; Genomics; Glioma; Micoarray; MiRNA; Oligodendroglioma; Personalized medicine; Pharmacogenetics

Indexed keywords

CARMUSTINE; CINTREDEKIN; CONNECTIVE TISSUE GROWTH FACTOR; CYTARABINE; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GALECTIN 1; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; METHYLATED METHYLGUANINE METHYLTRANSFERASE; METHYLTRANSFERASE; MICRORNA; MONOCLONAL ANTIBODY I 131; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; TEMOZOLOMIDE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TRANS MID; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; CANCER CHEMOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GLIOBLASTOMA; HUMAN; MICROARRAY ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; PHARMACOGENETICS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; VARIATION (GENETICS);

EID: 55349113571     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.4.525     Document Type: Review

References (83)

1. Murphy MP, Beaman ME, Clark LS et al.: Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a Phase III clinical trial. Pharmacogenetics 10(7), 583-590 (2000).
2. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
3. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
4. Mrugala MM, Kesari S, Ramakrishna N, Wen PY: Therapy for recurrent malignant glioma in adults. Expert Rev. Anticancer Ther. 4(5), 759-782 (2004).
5. Norden AD, Wen PY: Glioma therapy in adults. Neurologist 12(6), 279-292 (2006).
6. Bednar M: DNA microarray technology and application. Med Sci. Monit. 6(4), 796-800 (2000).
7. Hessner MJ, Meyer L, Tackes J. Muheisen S, Wang X: Immobilized probe and glass surface chemistry as variables in microarray fabrication. EMC Genomics 5 (1), 53 (2004).
8. Haab BB: Advances in protein microarray technology for protein expression and interaction profiling. Curr. Opin. Drug Discov. Devel. 4(1), 116-123 (2001).
9. Wu RZ, Bailey SN, Sabatini DM: Cell-biological applications of transfected-cell microarrays. Trends Cell. Biol. 12(10), 485-488(2002).
10. Clarke PA, te Poele R, Wooster R, Workman P: Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem. Pharmacol. 62(10), 1311-1336 (2001).
11. Schena M, Heller RA, Theriault TP, Konrad K, Lachenmeier E, Davis RW: Microarrays: biotechnology's discovery platform for functional genomics. Trends Biotechnol. 16(7), 301-306 (1998).
12. Hsiao LL, Stears RL, Hong RL, Gullans SR: Prospective use of DNA microarrays for evaluating renal function and disease. Curr. Opin. Nephrol. Hypertens. 9(3), 253-258 (2000).
13. Debouck C, Goodfellow PN: DNA microarrays in drug discovery and development. Nat. Genet. 21 (Suppl. 1), 48-50 (1999).
14. Kennedy GC: The impact of genomics on therapeutic drug development. EXS 89, 1-10 (2000).
15. Mullan PB, McWilliams S, Quinn J et al.: Uncovering BRCA1 -regulated signalling pathways by microarray-based expression profiling. Biochem. Soc. Trans. 29(Pt 6), 678-683 (2001).
16. Sardi I, Cavalieri D, Massimino M: Emerging treatments and gene expression profiling in high-risk medulloblastoma. Paediatr Drugs 9(2), 81-96 (2007).
17. de Groot JF, Gilbert MR: New molecular targets in malignant gliomas. Curr. Opin. Neurol. 20(6), 712-718 (2007).
18. Kawanishi Y, Tachikawa H, Suzuki T Pharmacogenomics and schizophrenia. Eur. J. Pharmacol. 410(2-3), 227-241 (2000).
19. Lai R, Hirsch-Ginsberg CF, Bueso-Ramos C: Pathologic diagnosis of acute lymphocytic leukemia. Hematol. Oncol. Clin. North Am. 14(6), 1209-1235 (2000).
20. Mariadason JM, Augenlicht LH, Arango D: Microarray analysis in the clinical management of cancer. Hematol. Oncol. Clin. North Am. 17(2), 377-387 (2003).
21. Shih IeM, Wang TL: Apply innovative technologies to explore cancer genome. Curr. Opin. Oncol. 17(1), 33-38 (2005).
22. Shi H, Maier S, Nimmrich I et al.: Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J. Cell. Biochem. 88(1), 138-143 (2003).
23. le Naour F: Contribution of proteomics to tumor immunology. Proteomics 1 (10), 1295-1302 (2001).
24. Ohgaki H, Dessen P, Jourde B et al.: Genetic pathways to glioblastoma: a population-based study. Cancer Res. 64(19), 6892-6899 (2004).
25. Griffin CA, Burger P, Morsberger L et al.: Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol. 65(10), 988-994 (2006).
26. Kim L, Glantz M: Chemotherapeutic options for primary brain tumors. Curr. Treat. Options Oncol. 7(6), 467-478 (2006).
27. Hoang-Xuan K, Capelle L, Kujas M et al.: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22(15), 3133-3138 (2004).
28. Cairncross G, Berkey B, Shaw E et al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol. 24(18), 2707-2714 (2006).
29. Penas-Prado M, Gilbert MR: Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev. Anticancer Ther. 7(5), 641-661 (2007).
30. Gilbert MR: Designing clinical trials for brain tumors: the next generation. Curr. Oncol, Rep. 9(1), 49-54 (2007).
31. Mellinghoff IK, Cloughesy TF, Mischel PS: PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 13 (2 Pt 1), 378-381 (2007).
32. Mehrian-Shai R, Chen CD, Shi T et al.: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and P13K/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl Acad. Sci. USA 104(13), 5563-5568 (2007).
33. Zumkeller W: IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? Mol. Pathol. 54(5), 285-288 (2001).
34. Tysnes BB, Mahesparan R: Biological mechanisms of glioma invasion and potential therapeutic targets. J. Neurooncol. 53(2), 129-147 (2001).
35. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (Suppl. 4), 2-8 (2002).
36. Yih TC, Al-Fandi M: Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 97(6), 1184-1190 (2006).
37. Kunwar S, Prados MD, Chang SM et al.: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25(7), 837-844 (2007).
38. Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK: Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol. Cancer Res. Treat. 5(3), 239-250 (2006).
39. Powathil G, Kohandel M, Sivaloganathan S, Oza A, Milosevic M: Mathematical modeling of brain tumors: effects of radiotherapy and chemotherapy. Phys. Med. Biol. 52(11), 3291-3306 (2007).
40. Reardon DA, Zalutsky MR, Bigner DD: Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7(5), 675-687 (2007).
41. Bao S, Wu Q, McLendon RE et al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756-760 (2006).
42. Brown JM: The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce E Cain Memorial Award lecture. Cancer Res. 59(23), 5863-5870 (1999).
43. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2(1), 38-47 (2002).
44. Eriksson S, Arner E, Spasokoukotskaja T et al.: Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv. Enzyme Regul. 34, 13-25 (1994).
45. Obata T, Endo Y, Tanaka M, Uchida H, Matsuda A, Sasaki T: Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J. Cancer Res. 92(7), 793-798 (2001).
46. Cuisnier O, Serduc R, Lavieille JP, Longuet M, Reyt E, Riva C: Chronic hypoxia protects against γ-irradiation-induced apoptosis by inducing bcl-2 up-regulation and inhibiting mitochondrial translocation and conformational change of bax protein. Int. J. Oncol. 23(4), 1033-1041 (2003).
47. Graeber TG, Osmanian C, Jacks T et al.: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560), 88-91 (1996).
48. Chen JK, Hu LJ, Wang D, Lamborn KR, Deen DF: Cytosine deaminase/ 5-fluoro-cytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int. J. Radiat. Oncol. Biol. Phys. 67(5), 1538-1547 (2007).
49. Chen S, Yu L, Jiang C et al.: Pivotal study of iodine- 131 -labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. 23(7), 1538-1547 (2005).
50. le Mercier M, Lefranc F, Mijatovic T et al.: Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol. Appl. Pharmacol. 229(2), 172-183 (2008).
51. Shai R, Shi T, Kremen TJ et al.: Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22(31), 4918-4923 (2003).
52. Freije WA, Castro-Vargas FE, Fang Z et al.: Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64(18), 6503-6510 (2004).
53. Phillips HS, Kharbanda S, Chen R et al.: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3), 157-173 (2006).
54. Bandres E, Andion E, Escalada A et al.: Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J. Neurooncol. 73(3), 189-198 (2005).
55. 6-alkylating agents in human glioblastomas. J. Clin. Oncol. 24(2), 274-287 (2006).
56. McLeod HL, Marsh S: Pharmacogenetics goes 3D. Nat. Genet. 37(8), 794-795 (2005).
57. Wilke RA, Reif DM, Moore JH: Combinatorial pharmacogenetics. Nat. Rev. Drug Discov. 4(11), 911-918 (2005).
58. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG: Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5(4), 226-243 (2005).
59. Dervieux T, Meshkin B, Neri B: Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat. Res. 573(1-2), 180-194 (2005).
60. Johansson M, Brismar S, Karlsson A: Human deoxycytidine kinase is located in the cell nucleus. Proc. Natl Acad. Sci. USA 94(22), 11941-11945 (1997).
61. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119(6), 985-989 (1991).
62. Lennard L, Gibson BE, Nicole T, Lilleyman JS: Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch. Dis. Child. 69(5), 577-579 (1993).
63. Mason W, Louis DN, Cairncross JG: Chemosensitive gliomas in adults: which ones and why? J. Clin. Oncol. 15(12), 3423-3426 (1997).
64. Weller M: Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 292(3), 435-445 (1998).
65. Korkaya H, Wicha MS: Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 21(5), 299-310 (2007).
66. Peller S: Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin. Cancer Biol. 8(5), 379-387 (1998).
67. Hanioka N, Ozawa S, Jinno H et al.: Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10- hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab. Dispos. 30(4), 391-396 (2002).
68. Costello JF, Plass C, Cavenee WK: Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathol. 17(2), 49-56 (2000).
69. Gonzalez-Gomez P, Bello MJ, Alonso ME et al.: CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br. J. Cancer 88(1), 109-114 (2003).
70. Alaminos M, Davalos V, Ropero S et al.: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 65(7), 2565-2571 (2005).
71. Waha A, Guntner S, Huang TH et al.: Epigenetic silencing of the protocadherin family member PCDH-γ-A11 in astrocytomas. Neoplasia 7(3), 193-199 (2005).
72. Hegi ME, Diserens AC, Gorlia T et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Eng]. J. Med. 352(10), 997-1003 (2005).
73. Bredel M, Bredel C, Juric D et al.: High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. Cancer Res. 65(10), 4088-4096 (2005).
74. Mukasa A, Ueki K, Matsumoto S et al.: Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 21(25), 3961-3968 (2002).
75. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004).
76. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS: A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9(10), 1274-1281 (2003).
77. Calin GA, Dumitru CD, Shimizu M et al.: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002).
78. Calin GA, Liu CG, Sevignani C et al.: MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101(32), 11755-11760 (2004).
79. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1(12), 882-891 (2003).
80. Ciafre SA, Galardi S, Mangiola A et al.: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 334(4), 1351-1358 (2005).
81. Kefas B, Godlewski J, Comeau L et al.: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 68(10), 3566-3572 (2008).
82. Lu Z, Liu M, Stribinskis V et al.: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31), 4373-4379 (2008).
83. Nicoloso MS, Calin GA: MicroRNA involvement in brain tumors: from bench to bedside. Brain Pathol. 18(1), 122-129 (2008).